Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by WalkOverTheStrton Jun 03, 2020 6:37pm

199 Views

Post# 31109028

RE:RE:RE:I Suspect

@MUGMODs well done on the predicitons.
When was your prediction for the drug to be sold at Phase? Post PH2B / before PH3, durng PH3, or after PH3?
I would prefer the whole company to be sold as their other assets are pre-clincial is memory serves.. get it done with so we SHs can exit.
My guess is entire co (if LTE aspects are confirmed to be caused outside of 346) will be $1B ($2.81)

Bullboard Posts

Sirios Resource discovers visible gold in Quebec